Gentium Announces Presentation of Preclinical and Clinical Data on Defibrotide at the 33rd World Congress of International Society of Hematology

 

 

VILLA GUARDIA (COMO), Italy, Sept. 14 /PRNewswire/ -- Gentium S.p.A. (NASDAQ:GENT) (the "Company") today announced that two posters and one oral presentation on defibrotide will be presented at the 33rd World Congress of International Society of Hematology to be held at the ICC Jerusalem International Convention Center in Jerusalem, Israel, October 10-13, 2010.
 

Poster Session 1, Tuesday, October 12, 2010:
 

"Defibrotide downregulates heparanase expression in tumor cells" (Abstract #330). C. Echart et. al., Gentium SpA, Como, Italy.
 

"Defibrotide protects endothelial cells from the complications of stem cell transplantation" (Abstract #335). C. Echart et al., Gentium SpA, Como, Italy.
 

Oral Presentation, Hall A, Wednesday, October 13, 2010:
 

"Defibrotide prevents acute Graft-versus-Host disease in pediatric stem cell transplantation: results of the prospective phase II/III VOD-DF trial" (Abstract #386, ). S. Corbacioglu et al., University of Regensburg, Germany.
 

For more details on the congress, please visit the official congress web site:
 

  
http://www2.kenes.com/hematology/pages/home.aspx.

  About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. FDA and Orphan Medicinal Product Designation by the European Commission both to treat and to prevent VOD and Fast Track Designation by the U.S. FDA to treat VOD.
 

Cautionary Note Regarding Forward-Looking Statements
 

This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to any financial forecast or the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."
 

  Gentium S.p.A.
  Salvatore Calabrese, +39 031-385-287
  Senior Vice President, Finance
  scalabrese@gentium.it

  or

  The Trout Group
  Marcy Nanus, +1 646-378-2927
  mnanus@troutgroup.com

Source: Gentium S.p.A.

CONTACT: Gentium S.p.A., Salvatore Calabrese, +39-031-385-287, Senior
Vice President, Finance, scalabrese@gentium.it; or The Trout Group, Marcy
Nanus, +1-646-378-2927, mnanus@troutgroup.com
 

Web Site: http://www2.kenes.com/hematology/pages/home.aspx
 

Posted: September 2010

View comments

Hide
(web2)